Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
Cicatricial pemphigoid is an autoimmune blistering disease which affects the skin, mucous
membranes, and, in a small subset of patients, the eye. Progressive ocular disease can lead
to irreversible damage and blindness. Conventional treatments include systemic steroids,
dapsone, and immunosuppressive agents. These treatments, however, are not successful with all
patients. Rituximab has been very effective in the treatment of other autoimmune disorders,
and has recently been shown to be effective for autoimmune blistering pemphigus. We propose
that it will also be effective in the treatment of cicatricial pemphigoid.